Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 2 2Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 9Active not recruiting 5Completed 4Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Leukemia, Myeloid, Acute 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Practice Guidelines as Topic × Clear all
NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Mayo Clinic

Phase 2 Terminated
20 enrolled 13 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT03108911 2017-11-17

Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Rutgers, The State University of New Jersey

Phase 2 Terminated
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡